<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070380</url>
  </required_header>
  <id_info>
    <org_study_id>MH-148</org_study_id>
    <nct_id>NCT02070380</nct_id>
  </id_info>
  <brief_title>Crossover Comparison of MultiHance and Dotarem</brief_title>
  <acronym>BENEFIT</acronym>
  <official_title>Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in MRI of the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg
      and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of
      MultiHance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This crossover study aims at a comparison between 0.1 mmol/kg MultiHance and 0.1 mmol/kg
      Dotarem, between 0.05 MultiHance and 0.1 mmol/kg Dotarem in terms of diagnostic preference at
      CE-MRI in brain tumor patients to show superiority of MultiHance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Diagnostic Preference Between the Two Exams</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion Border Delineation</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Internal Morphology</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of Disease</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Contrast Enhancement</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion to Background Ratio on Post T1-weighed Spin Echo Images</measure>
    <time_frame>5-10 minutes Postdose</time_frame>
    <description>The Unit of Measure is lesion-to-background ratio based on lesions assessed. For each lesion, Lesion-to-background ratio (LBR) = SI of lesion/SI of brain. Firstly, LBR of each lesion was assessed for each contrast agent postdose image separately, then the difference in LBR between MultiHance and Dotarem was calculated. The number presented in the result table below is &quot;the mean difference in LBR postdose (MultiHance - Dotarem)&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion-brain Contrast-to-noise Ratio</measure>
    <time_frame>5-10 minutes Postdose</time_frame>
    <description>The Unit of Measure is contrast-to-noise ratio based on lesions assessed. For each lesion, Lesion-brain Contrast-to-noise Ratio (CNR) = [(SI of lesion - SI of brain)/SD for SI of noise] on Postdose Images of each lesion was calculated for each contrast agent image separately, then the difference in CNR between MultiHance and Dotarem was calculated. The number presented in the result table below is &quot;the mean difference in CNR (MultiHance - Dotarem)&quot;</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Brain Disease</condition>
  <arm_group>
    <arm_group_label>MultiHance 0.1 then Dotarem 0.1 mmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MultiHance 0.05 then Dotarem 0.1 mmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dotarem 0.1 then MultiHance 0.1 mmol/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dotarem 0.1 then MultiHance 0.05 mmol/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MultiHance 0.1 mmol/kg</intervention_name>
    <description>MultiHance administered at 0.1 mmol/kg</description>
    <arm_group_label>MultiHance 0.1 then Dotarem 0.1 mmol/kg</arm_group_label>
    <arm_group_label>Dotarem 0.1 then MultiHance 0.1 mmol/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dotarem</intervention_name>
    <description>Dotarem administered at 0.1 mmol/kg</description>
    <arm_group_label>MultiHance 0.1 then Dotarem 0.1 mmol/kg</arm_group_label>
    <arm_group_label>MultiHance 0.05 then Dotarem 0.1 mmol/kg</arm_group_label>
    <arm_group_label>Dotarem 0.1 then MultiHance 0.1 mmol/kg</arm_group_label>
    <arm_group_label>Dotarem 0.1 then MultiHance 0.05 mmol/kg</arm_group_label>
    <other_name>Dotarem 0.1 mmol/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MultiHance 0.05 mmol/kg</intervention_name>
    <description>MultiHance administered at 0.05 mmol/kg</description>
    <arm_group_label>MultiHance 0.05 then Dotarem 0.1 mmol/kg</arm_group_label>
    <arm_group_label>Dotarem 0.1 then MultiHance 0.05 mmol/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are at least 18 years of age or older

          -  Are able to give written informed consent and are willing to comply with the protocol
             requirements

          -  Are scheduled to undergo MRI

          -  Are willing to undergo two MRI procedures within 14 days

          -  Have confirmed or are highly suspected to have brain tumor(s) (primary or secondary),
             as determined by:

          -  Clinical/neurological symptomatology;

          -  Diagnostic testing, such as CT or previous MRI examinations; or

          -  Have had recent brain surgery and are to be evaluated for recurrence

        Exclusion Criteria:

          -  Are pregnant or lactating females. Exclude the possibility of pregnancy:

          -  By testing on site at the institution within 24 hours prior to the start of each
             investigational product administration; or

          -  By history (i.e., tubal ligation or hysterectomy); or

          -  Post menopausal with a minimum of 1 year without menses

          -  Have any known allergy to one or more of the ingredients in the investigational
             products, or have a history of hypersensitivity to any metals

          -  Have congestive heart failure (class IV according to the classification of the New
             York Heart Association)

          -  Have suffered a stroke within a year

          -  Have received or are scheduled to receive any other contrast medium in the 24 hours
             preceding through the 24 hours following Exam 1, and in the 24 hours preceding through
             the 24 hours following Exam 2

          -  Have received or are scheduled to receive an investigational compound and/or medical
             device within 30 days before admission into the present study, through the 24 hours
             post-administration of the second investigational product

          -  Have moderate-to-severe renal impairment, defined as Glomerular Filtration Rate
             (GFR)/estimated GFR &lt; 45 mL/min

          -  Have been previously entered into this study

          -  Have received or are scheduled for one of the following:

          -  Surgical or chemotherapeutic treatment within three weeks prior to the first
             examination or between the two examinations

          -  Initiation of steroid therapy between the two examinations

          -  Radiosurgery between the two examinations

          -  Have any contraindications to MRI such as a pace-maker, magnetic material (i.e.,
             surgical clips) or any other conditions that would preclude proximity to a strong
             magnetic field

          -  Are suffering from severe claustrophobia

          -  Have any medical condition or other circumstances which would significantly decrease
             the chances of obtaining reliable data, achieving study objectives, or completing the
             study and/or post-dose follow-up examinations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianpaolo Pirovano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bracco Diagnostics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samaritan Health Services</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <results_first_submitted>July 8, 2016</results_first_submitted>
  <results_first_submitted_qc>November 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2017</results_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>confirmed brain disease</keyword>
  <keyword>highly suspected brain disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 179 patients were recruited from February 2014 through February 2015 at 14 clinical trial sites. Off-site assessment of the images was performed between 19 February – 17 March 2015 by 3 board-certified neuroradiologists blinded as to which contrast agent was used, patient clinical information, and the results of other imaging studies.</recruitment_details>
      <pre_assignment_details>179 patients were enrolled and signed informed consent. Each enrolled patient was randomized and 177 were dosed with at least one contrast agent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg</title>
          <description>Patients randomized to receive MultiHance 0.1 mmol/kg first</description>
        </group>
        <group group_id="P2">
          <title>Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg</title>
          <description>Patients randomized to receive Dotarem 0.1 mmol/kg first</description>
        </group>
        <group group_id="P3">
          <title>MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg</title>
          <description>Patients randomized to receive MultiHance 0.05 mmol/kg first</description>
        </group>
        <group group_id="P4">
          <title>Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg</title>
          <description>Patients randomized to receive Dotarem 0.1 mmol/kg first</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Injection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (no Second Injection/MRI)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Injection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Image sets missing or technically inadeq</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg</title>
          <description>Patients randomized to receive MultiHance 0.1 mmol/kg first</description>
        </group>
        <group group_id="B2">
          <title>Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg</title>
          <description>Patients randomized to receive Dotarem 0.1 mmol/kg first</description>
        </group>
        <group group_id="B3">
          <title>MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg</title>
          <description>Patients randomized to receive MultiHance 0.05 mmol/kg first</description>
        </group>
        <group group_id="B4">
          <title>Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg</title>
          <description>Patients randomized to receive Dotarem 0.1 mmol/kg first</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="46"/>
            <count group_id="B5" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Diagnostic Preference Between the Two Exams</title>
        <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <population>Per Protocol=patients who completed both exams, had global paired image data available, and had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O2">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O3">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O4">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O5">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O6">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Global Diagnostic Preference Between the Two Exams</title>
          <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
          <population>Per Protocol=patients who completed both exams, had global paired image data available, and had no major protocol violations</population>
          <units>participant exams</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MultiHance Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contrast Agents Equal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="56"/>
                    <measurement group_id="O6" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dotarem Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of global diagnostic preference in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Only 1 primary endpoint, no adjustment for multiple comparisons and the a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed-rank test.</method>
            <param_type>∆Percentage MH better minus DM better</param_type>
            <param_value>47.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.5</ci_lower_limit>
            <ci_upper_limit>60.7</ci_upper_limit>
            <estimate_desc>Difference in percentage MultiHance better minus percentage Dotarem better (%) , 2-sided 95% confidence interval was estimated using Altman’s general approximate normal method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of global diagnostic preference in an off-site pre-dose plus post-dose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1295</p_value>
            <p_value_desc>Only 1 primary endpoint, no adjustment for multiple comparisons and the a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed-rank test.</method>
            <param_type>∆Percentage MH better minus DM better</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>16.5</ci_upper_limit>
            <estimate_desc>Difference in percentage MultiHance better minus percentage Dotarem better (%) , 2-sided 95% confidence interval was estimated using Altman’s general approximate normal method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of global diagnostic preference in an off-site pre-dose plus postdose paired global assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Only 1 primary endpoint, no adjustment for multiple comparisons and the a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed rank test</method>
            <param_type>∆Percentage MH better minus DM better</param_type>
            <param_value>79.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.1</ci_lower_limit>
            <ci_upper_limit>91.0</ci_upper_limit>
            <estimate_desc>Difference in percentage MultiHance better minus percentage Dotarem better (%) , 2-sided 95% confidence interval was estimated using Altman’s general approximate normal method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of global diagnostic preference in an off-site pre-dose plus post-dose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7503</p_value>
            <p_value_desc>Only 1 primary endpoint, no adjustment for multiple comparisons and the a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed rank test</method>
            <param_type>Percentage MH better minus DM better</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.0</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
            <estimate_desc>Difference in percentage MultiHance better minus percentage Dotarem better (%) , 2-sided 95% confidence interval was estimated using Altman’s general approximate normal method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of global diagnostic preference in an off-site pre-dose plus post-dose paired global assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Only 1 primary endpoint, no adjustment for multiple comparisons and the a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed rank test</method>
            <param_type>∆Percentage MH better minus DM better</param_type>
            <param_value>66.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>52.8</ci_lower_limit>
            <ci_upper_limit>79.5</ci_upper_limit>
            <estimate_desc>Difference in percentage MultiHance better minus percentage Dotarem better (%) , 2-sided 95% confidence interval was estimated using Altman’s general approximate normal method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of global diagnostic preference in an off-site pre-dose plus post-dose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7297</p_value>
            <p_value_desc>Only 1 primary endpoint, no adjustment for multiple comparisons and the a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed rank test</method>
            <param_type>∆Percentage MH better minus DM better</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
            <estimate_desc>Difference in percentage MultiHance better minus percentage Dotarem better (%) , 2-sided 95% confidence interval was estimated using Altman’s general approximate normal method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Border Delineation</title>
        <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O2">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O3">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O4">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O5">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O6">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Border Delineation</title>
          <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
          <units>participant exams</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MultiHance Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contrast Agents Equal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="66"/>
                    <measurement group_id="O6" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dotarem Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This is a secondary analysis.
Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Border Delineation in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is a secondary analysis.
Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Border Delineation in an off-site pre-dose plus post-dose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8238</p_value>
            <p_value_desc>The priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is a secondary analysis.
Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Border Delineation in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>This is a secondary analysis.
Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Border Delineation in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4597</p_value>
            <p_value_desc>The priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a secondary analysis.
Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Border Delineation in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>This is a secondary analysis.
Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Border Delineation in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8145</p_value>
            <p_value_desc>The priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon signed rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Internal Morphology</title>
        <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O2">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O3">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O4">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O5">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O6">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Internal Morphology</title>
          <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
          <units>participant exams</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MultiHance better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Difference Between MultiHance and Dotarem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="87"/>
                    <measurement group_id="O6" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dotarem better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Internal Morphology in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Internal Morphology in an off-site pre-dose plus post-dose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Internal Morphology in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Internal Morphology in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Internal Morphology in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Internal Morphology in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5811</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Disease</title>
        <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O2">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O3">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O4">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O5">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O6">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Disease</title>
          <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
          <units>participant exams</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MultiHance Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Difference between MultiHance and Dotarem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="83"/>
                    <measurement group_id="O6" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dotarem Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Extent of Disease in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Extent of Disease in an off-site pre-dose plus post-dose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Extent of Disease in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Extent of Disease in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Extent of Disease in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Extent of Disease in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Contrast Enhancement</title>
        <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O2">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O3">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O4">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O5">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O6">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Contrast Enhancement</title>
          <description>Assessed by 3 blinded readers for each of the 159 patients who had post-dose exams for both MultiHance, 0.1 mmol/kg and 0.05 mmol/kg doses, and Dotarem 0.1 mmol/kg. Readers assessed whether images with MultiHance were preferred or images with Dotarem were preferred, or whether images after both exams were considered equal. An image set deemed technically inadequate by a blinded reader was excluded from efficacy analysis for that specific reader. Therefore, the number of participant exams evaluated by each reader differed slightly across readers and endpoints.</description>
          <units>Participant Exams</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MultiHance Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Difference between MultiHance and Dotarem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="56"/>
                    <measurement group_id="O6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dotarem Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Contrast Enhancement in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Contrast Enhancement in an off-site pre-dose plus post-dose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Contrast Enhancement in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Contrast Enhancement in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7503</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.1 mmol/kg dose of MULTIHANCE is equal to a 0.1 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Contrast Enhancement in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses:
A 0.05 mmol/kg dose of MULTIHANCE is equal to a 0.05 mmol/kg dose of DOTAREM, in terms of the assessment of Lesion Contrast Enhancement in an off-site pre-dose plus postdose paired global assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5983</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion to Background Ratio on Post T1-weighed Spin Echo Images</title>
        <description>The Unit of Measure is lesion-to-background ratio based on lesions assessed. For each lesion, Lesion-to-background ratio (LBR) = SI of lesion/SI of brain. Firstly, LBR of each lesion was assessed for each contrast agent postdose image separately, then the difference in LBR between MultiHance and Dotarem was calculated. The number presented in the result table below is “the mean difference in LBR postdose (MultiHance – Dotarem)”</description>
        <time_frame>5-10 minutes Postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O2">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O3">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O4">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O5">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O6">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion to Background Ratio on Post T1-weighed Spin Echo Images</title>
          <description>The Unit of Measure is lesion-to-background ratio based on lesions assessed. For each lesion, Lesion-to-background ratio (LBR) = SI of lesion/SI of brain. Firstly, LBR of each lesion was assessed for each contrast agent postdose image separately, then the difference in LBR between MultiHance and Dotarem was calculated. The number presented in the result table below is “the mean difference in LBR postdose (MultiHance – Dotarem)”</description>
          <units>ratio based on lesions assessed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="95"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.24"/>
                    <measurement group_id="O2" value="0.24" spread="0.20"/>
                    <measurement group_id="O3" value="0.21" spread="0.23"/>
                    <measurement group_id="O4" value="-0.01" spread="0.21"/>
                    <measurement group_id="O5" value="0.03" spread="0.15"/>
                    <measurement group_id="O6" value="0.01" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with period, sequence, and IP and fixed effect and subject nested within sequence as random effect</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6898</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with period, sequence, and IP and fixed effect and subject nested within sequence as random effect</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with period, sequence, and IP and fixed effect and subject nested within sequence as random effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1156</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with period, sequence, and IP and fixed effect and subject nested within sequence as random effect</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7726</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion-brain Contrast-to-noise Ratio</title>
        <description>The Unit of Measure is contrast-to-noise ratio based on lesions assessed. For each lesion, Lesion-brain Contrast-to-noise Ratio (CNR) = [(SI of lesion - SI of brain)/SD for SI of noise] on Postdose Images of each lesion was calculated for each contrast agent image separately, then the difference in CNR between MultiHance and Dotarem was calculated. The number presented in the result table below is &quot;the mean difference in CNR (MultiHance - Dotarem)&quot;</description>
        <time_frame>5-10 minutes Postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O2">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O3">
            <title>MultiHance 0.1 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.1 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O4">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 1)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O5">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 2)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
          <group group_id="O6">
            <title>MultiHance 0.05 mmol/kg Arm (Reader 3)</title>
            <description>MRI with MultiHance 0.05 mmol/kg versus MRI with Dotarem 0.1 mmol/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion-brain Contrast-to-noise Ratio</title>
          <description>The Unit of Measure is contrast-to-noise ratio based on lesions assessed. For each lesion, Lesion-brain Contrast-to-noise Ratio (CNR) = [(SI of lesion - SI of brain)/SD for SI of noise] on Postdose Images of each lesion was calculated for each contrast agent image separately, then the difference in CNR between MultiHance and Dotarem was calculated. The number presented in the result table below is &quot;the mean difference in CNR (MultiHance - Dotarem)&quot;</description>
          <units>ratio based on lesions assessed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="95"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.40" spread="36.14"/>
                    <measurement group_id="O2" value="31.82" spread="45.28"/>
                    <measurement group_id="O3" value="39.73" spread="65.26"/>
                    <measurement group_id="O4" value="15.72" spread="36.05"/>
                    <measurement group_id="O5" value="19.06" spread="29.37"/>
                    <measurement group_id="O6" value="23.03" spread="49.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Investigation product (IP) effect from mixed model with period, sequence, and IP as fixed effects and subject nested within sequence as random effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Investigation product (IP) effect from mixed model with period, sequence, and IP as fixed effects and subject nested within sequence as random effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Investigation product (IP) effect from mixed model with period, sequence, and IP as fixed effects and subject nested within sequence as random effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Investigation product (IP) effect from mixed model with period, sequence, and IP as fixed effects and subject nested within sequence as random effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Investigation product (IP) effect from mixed model with period, sequence, and IP as fixed effects and subject nested within sequence as random effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Investigation product (IP) effect from mixed model with period, sequence, and IP as fixed effects and subject nested within sequence as random effect.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 hours after contrast media injection</time_frame>
      <desc>All adverse events collected were categorized using MedDRA 17.1 and tabulated</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Arm 1 / MultiHance 0.1 mmol/kg</title>
          <description>Study Arm 1: MultiHance 0.1 mmol/kg/ Experienced after dosed with MultiHance 0.1 mmol/kg.
31 (MH as 1st injection) + 34 (MH as 2nd injection) = 65</description>
        </group>
        <group group_id="E2">
          <title>Study Arm 1 / Dotarem 0.1 mmol/kg</title>
          <description>Study Arm 1: MultiHance 0.1 mmol/kg/ Experienced after dosed with Dotarem 0.1 mmol/kg.
39 (Dotarem as 1st injection) + 31 (Dotarem as 2nd injection) =70</description>
        </group>
        <group group_id="E3">
          <title>Study Arm 2/ MultiHance 0.05 mmol/kg</title>
          <description>Study Arm 2: MultiHance 0.05 mmol/kg/ Experienced after dosed with MultiHance 0.05 mmol/kg.
53 (MH as 1st injection) + 51 (MH as 2nd injection) = 104</description>
        </group>
        <group group_id="E4">
          <title>Study Arm 2 / Dotarem 0.1 mmol/kg</title>
          <description>Study Arm 2: MultiHance 0.05 mmol/kg/ Experienced after dosed with Dotarem 0.1 mmol/kg.
54 (Dotarem as 1st injection) + 51 (Dotarem as 2nd injection) =105</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study results may be presented at scientific symposia or published in a peer-review journal after review by sponsor in accordance with the guidelines set forth in the applicable publication or financial agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gianpaolo Pirovano, MD</name_or_title>
      <organization>Bracco Diagnostics, Inc.</organization>
      <phone>609-514-2226</phone>
      <email>gianpaolo.pirovano@diag.bracco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

